• 1. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002
• 2. An amide probe as a selective Al3+ and Fe3+ sensor inside the HeLa and a549 cell lines: Pictet–Spengler reaction for the rapid detection of tryptophan amino acid?
  Bidyut Kumar Kundu,Rinky Singh,Ritudhwaj Tiwari,Debasis Nayak New J. Chem., 2019,43, 4867-4877
• 3. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli
• 4. An antioxidant self-healing hydrogel for 3D cell cultures?
  Lei Yang,Yuan Zeng,Haibo Wu,Chunwu Zhou,Lei Tao J. Mater. Chem. B, 2020,8, 1383-1388
• 5. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526

Introduction to 8-Quinazolinol, 5,7-dibromo-2-chloro (CAS No. 2570190-10-0)

8-Quinazolinol, 5,7-dibromo-2-chloro, identified by its Chemical Abstracts Service (CAS) number 2570190-10-0, is a significant compound in the realm of pharmaceutical chemistry and medicinal research. This heterocyclic aromatic molecule has garnered attention due to its structural complexity and potential biological activities. The presence of bromine and chlorine substituents at specific positions in its quinazoline backbone enhances its reactivity, making it a valuable scaffold for drug discovery and development.

The quinazoline core is a well-known pharmacophore in medicinal chemistry, frequently employed in the design of bioactive molecules targeting various diseases. The bromo and chloro substitutions at the 5, 7, and 2 positions, respectively, introduce electrophilic centers that can participate in nucleophilic aromatic substitution (SNAr) reactions. This feature makes 8-Quinazolinol, 5,7-dibromo-2-chloro a versatile intermediate for synthesizing more complex derivatives with tailored pharmacological properties.

In recent years, there has been a surge in research focused on quinazoline derivatives due to their demonstrated efficacy against cancer, infectious diseases, and inflammatory conditions. The bromo and chloro substituents not only facilitate further functionalization but also influence the compound's electronic properties, thereby modulating its interactions with biological targets. This dual functionality has been exploited in the development of kinase inhibitors, which are crucial in oncology therapy.

One of the most compelling aspects of 8-Quinazolinol, 5,7-dibromo-2-chloro is its potential as a lead compound for antitumor agents. Quinazoline-based kinase inhibitors have shown promise in preclinical studies by selectively inhibiting aberrantly activated kinases that drive tumor growth. The bromine atoms at the 5 and 7 positions provide handles for further derivatization through cross-coupling reactions such as Suzuki-Miyaura or Buchwald-Hartwig couplings. These reactions allow for the introduction of aryl or heteroaryl groups, expanding the compound's pharmacological spectrum.

Moreover, the chloro substituent at the 2-position can be leveraged for palladium-catalyzed coupling reactions with amines or thiols, enabling the construction of more intricate molecular architectures. Such modifications have been pivotal in enhancing binding affinity and selectivity against target enzymes. The ability to systematically vary substituents while retaining the quinazoline core makes 8-Quinazolinol, 5,7-dibromo-2-chloro an indispensable tool in medicinal chemistry.

The synthesis of 8-Quinazolinol, 5,7-dibromo-2-chloro typically involves multi-step organic transformations starting from commercially available precursors. A common synthetic route includes bromination and chlorination of a parent quinazoline derivative followed by functional group interconversion. Advanced techniques such as transition-metal catalysis and flow chemistry have been employed to optimize yields and purity.

Recent advancements in computational chemistry have further accelerated the design of quinazoline-based drugs. Molecular modeling studies have revealed that small modifications around the quinazoline scaffold can significantly alter binding interactions with protein targets. This knowledge has been instrumental in guiding synthetic strategies to improve drug-like properties such as solubility and metabolic stability.

In clinical settings, derivatives of 8-Quinazolinol, 5,7-dibromo-2-chloro are being evaluated for their therapeutic potential in oncology. Preclinical data suggest that certain quinazoline kinase inhibitors exhibit potent antitumor activity by disrupting signaling pathways essential for cancer cell proliferation. The bromine and chlorine atoms play a critical role in fine-tuning these interactions, ensuring high specificity against disease-causing kinases while minimizing off-target effects.

The versatility of 8-Quinazolinol, 5,7-dibromo-2-chloro extends beyond oncology; it has also shown promise in combating infectious diseases caused by viruses and bacteria. Quinazoline derivatives have demonstrated antiviral properties by inhibiting viral replication enzymes or disrupting host-virus interactions. The structural features of this compound make it an attractive candidate for developing novel antibiotics as well.

As research continues to uncover new therapeutic applications for quinazoline derivatives, 8-Quinazolinol, 5,7-dibromo-2-chloro remains at the forefront of drug discovery efforts. Its unique structural attributes provide a rich foundation for generating novel bioactive molecules with broad therapeutic relevance. The ongoing development of synthetic methodologies and computational tools will further enhance our ability to harness this compound's potential.

The future directions for 8-Quinazolinol, 5,7-dibromo-2-chloro include exploring its role in precision medicine initiatives aimed at personalizing cancer treatments based on genetic profiles of patients. By integrating structural biology insights with high-throughput screening technologies, researchers can identify optimized derivatives with enhanced efficacy and reduced toxicity profiles.

In conclusion,8-Quinazolinol, 5, 7-dibromo, 2-chloro (CAS No. 2570190/10/0) represents a cornerstone compound in modern pharmaceutical research due to its structural complexity and functional diversity. Its potential applications span multiple therapeutic areas underscored by its role as a versatile scaffold for drug development efforts aimed at addressing unmet medical needs.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)